Ruth Loos, PhD
img_Ruth Loos
PROFESSOR | Environmental Medicine & Public Health
Research Topics
Diabetes, Genetics, Genomics, Human Genetics and Genetic Disorders, Molecular Epidemiology, Obesity
Previous positions

Ruth obtained her PhD at the University of Leuven (Belgium) in 2001, after which she was a postdoctoral fellow at the Pennington Biomedical Research Center in Baton Rouge (LA, USA) in Dr Claude Bouchard’s Human Genetics laboratory. There, her research mainly concerned the identification of genetic variants for energy expenditure and fat oxidation through linkage and association studies. In July 2005, she joined the MRC Epidemiology Unit of the Institute of Metabolic Science in Cambridge (England) to become Group Leader of the Genetic Aetiology of Obesity Programme. She also lectured at Department of Genetics of the University of Cambridge. Ruth joined the Mount Sinai School of Medicine in New York in December 2011, and remains an honorary member of the MRC Epidemiology Unit in Cambridge.

Research Interests

Ruth's primary research interests focus on the identification of genes and genetic loci contributing to the risk of obesity and related metabolic traits. She has been involved in gene - discovery since 2005, when ‘genome - wide association’ was introduced and has since actively contributed to many consortia that use this approach to identify genetic loci for a large number of metabolic traits. Increasingly, her gene - discovery work also focuses on the identification of low - frequency variants through the implementation exome - chip genotyping and sequencing projects, not only in individuals of white European descent, but also in those of African and Hispanic decent.

She is a member of steering committee of the GIANT (Genetic Investigation of ANTropometric Traits) consortium, led by Professor Joel Hirschhorn and is actively involved in the many working groups. She has set up the Genome - Wide Association Study (GWAS) consortia for body fat percentage, for leptin levels, and also for resting heart rate. Furthermore, she has been involved in the GWAS consortia for blood pressure (ICBP), lipids (GLGC), glucose and insulin (MAGIC), and type 2 diabetes (DIAGRAM), amongst others.   

Besides gene-discovery, she uses epidemiological methods to follow - up on established loci with the aim to elucidate the pathways through which they increase risk of metabolic disease. Furthermore, her work also assesses the public health implications of the established loci by examining their predictive value and their interaction with lifestyle factors such as diet and physical activity.

Research Interests:
  • Gene-discovery for obesity and related metabolic traits
  • Role of low-frequency variants in metabolic traits
  • Genetic contribution to obesity and related metabolic traits in individuals of African and Hispanic origin
  • Gene-environment interaction to study the influence of lifestyle on the genetic susceptibility to obesity and related metabolic traits
  • The value of genetic prediction for obesity and related metabolic disease
  • Use of epidemiological methods to gain insights in the pathways that connect genetic loci to increased risk of disease

Updated list of publications.

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Loos during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Scientific Advisory Board:

  • University of Copenhagen

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.